Drug Reform Unlikely to Affect Small Biotech Companies

By: ETFdb
Investing in healthcare stocks is compelling for many investors because of the defensive qualities of blue chip pharmaceuticals companies and the growth prospects of biotechnology names.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.